Trial of High-dose Urso in Primary Sclerosing Cholangitis
Status:
Terminated
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, controlled trial of high dose ursodiol versus placebo for
patients with primary sclerosing cholangitis (PSC). The average duration of follow-up will be
approximately five years with important clinical endpoints such as death, eligibility for
liver transplantation, changes in histology and cholangiogram as well as liver biochemistries
and quality of life data collected.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)